Algemeen Stedelijk Ziekenhuis Campus Aalst
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Algemeen Stedelijk Ziekenhuis Campus Aalst, clinical research in cardiovascular diseases focuses on reducing the burden of coronary artery disease, non-obstructive coronary artery disease, and atrial fibrillation-related stroke risk. These studies are designed to test new treatment strategies and improve prevention for people at elevated heart risk.
- Evaluating lipid-lowering therapies for people at high risk of heart attack and stroke
- Studying approaches to slow or reduce coronary plaque progression in coronary artery disease
- Assessing anticoagulation strategies to lower embolic events after atrial fibrillation treatment
This area of research aims to improve long-term cardiovascular protection and help identify better ways to prevent serious events before they occur.
Musculoskeletal Diseases
Research in musculoskeletal diseases at this hospital includes peripheral spondyloarthritis, with a focus on finding more effective ways to bring inflammation under control and support remission. The work compares established treatment pathways with newer biologic-based approaches.
- Investigating treatment strategies for inflammatory joint disease
- Comparing conventional therapies with early biologic intervention
- Exploring options to improve symptom control and remission rates
The goal is to refine care for people with chronic inflammatory rheumatic conditions and improve outcomes through more targeted treatment choices.
Nutritional and Metabolic Diseases
Clinical trials in nutritional and metabolic diseases address obesity and type 2 diabetes, with a strong emphasis on weight management and metabolic health. These studies are testing whether new therapies can support weight loss and improve control of diabetes alongside lifestyle changes.
- Evaluating treatments for overweight and obesity in people with diabetes
- Studying therapies that may help improve weight and blood sugar control
- Supporting better cardiometabolic risk reduction through new treatment options
This research reflects growing interest in therapies that may help patients manage both excess weight and diabetes more effectively.
Virus Diseases
The virus diseases portfolio at Algemeen Stedelijk Ziekenhuis Campus Aalst includes studies in chronic hepatitis B infection. The research is focused on understanding treatment interruption and viral outcomes, with the broader aim of improving long-term management of this persistent infection.
- Examining outcomes after stopping antiviral treatment in chronic hepatitis B
- Investigating factors that may influence viral control over time
- Supporting better strategies for managing long-term hepatitis B care
This work is intended to help clarify which patients may benefit from different treatment approaches and to inform safer, more personalized care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 59 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 48 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1St. Antonius Ziekenhuis2active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1St. Antonius Ziekenhuis3trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Algemeen Stedelijk Ziekenhuis Campus Aalst
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Study of JNJ-78278343 and Docetaxel Versus Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer | Janssen Cilag International | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 59 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 3 | Unknown | 2018-01-12 | 2023-12-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.